Who makes SER120 Nasal Spray 500 ng/day?

SER120 Nasal Spray 500 ng/day is developed by Serenity Pharmaceuticals, Inc..

What development phase is SER120 Nasal Spray 500 ng/day in?

SER120 Nasal Spray 500 ng/day is in Phase 3.

Last reviewed 2026-05-13 · How we verify

SER120 Nasal Spray 500 ng/day

Serenity Pharmaceuticals, Inc. · Phase 3 active Small molecule

SER120 is an investigational nasal spray formulation with an unknown mechanism of action.

At a glance

Generic name	SER120 Nasal Spray 500 ng/day
Sponsor	Serenity Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

SER120 is a Phase 3 candidate from Serenity Pharmaceuticals administered as a nasal spray at 500 ng/day. Without publicly disclosed mechanism information, the specific molecular target and therapeutic pathway remain undetermined. Further clinical trial data would be needed to characterize its pharmacological action.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SER120 Nasal Spray 500 ng/day CI brief — competitive landscape report
SER120 Nasal Spray 500 ng/day updates RSS · CI watch RSS
Serenity Pharmaceuticals, Inc. portfolio CI